Career Opportunity

Supply Chain Support Specialist – US

At Life Molecular Imaging, we believe that our statement of “More Than a Job. It’s Making Life Better” goes beyond the population we serve. It extends to our culture of creating a welcoming, safe, and inclusive work environment for everyone. We are proud to be an Equal Opportunity Employer and all qualified applicants will receive consideration for employment.  

Supply Chain Support Specialist - US

Summary of Position:
Assist the Head of Supply Chain in US in coordinating production, purchasing, booking logistic services and implementing activities to limit costs and improve process execution accuracy to strengthen the order-to-cash (O2C) cycle.

Essential Responsibilities & Requirements (not all inclusive):

  • Arrange transportation where required based on existing order book.
  • Preparing documents to support transportation requirements.
  • Liaise with distributors and manufacturers to establish guidelines on transportation-road and air with the objective of reducing and optimizing cost.
  • Setup automation and setting up process with 3PL.
  • Monitor logistic costs and control points for all logistic related invoicing.
  • Custodian of setting up the invoicing systems with contract details / master data related to Order to cash.
  • Analyze data entries to ensure accuracy and define data anomalies.
  • Work closely with Customer service teams to help communicate with customers on Logistic delays and remedies.
  • Troubleshooting real-time logistic issues and triage with entities involved.

What we expect:
To be successful in this role, you must be able to handle working in a time sensitive role with pivoting priorities. You will need to be stress tolerant, highly organized, proactive, flexible, and resourceful while working with multiple projects. Candidate must have bachelor’s degree in relevant field such as business, logistics or supply chain management. Certification as a Supply Chain Professional and two years direct experience may be substituted for a degree. Must have developed experience in Supply Chain management activities including data analysis, systems thinking, project management, supply chain planning. We are looking for people who are just as passionate as we are to improving the lives of those with Alzheimer’s and other neurodegenerative diseases.  

What you can expect: 
Candidates who are up for a challenge will be supported by their coworkers, managers, and other divisions of a global company. You will be able to make significant contributions through your expertise. You can expect what YOU do to matter, as all our employees are an integral part of a global organization as well as the communities we serve.  

Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.



  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.


  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).


  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.


  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.